苑东生物(688513.SH)参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drug products after the expiration of the national organized procurement agreements, with 13 products, including Bisoprolol Fumarate Tablets and Etoricoxib Tablets, proposed for selection in this procurement [1] Group 1 - The procurement process is led by Jiangsu, Henan, and Guangdong provinces, aiming to stabilize or further reduce prices while providing greater choice for medical institutions [1] - The selection of products allows medical institutions to choose suppliers with better supply assurance capabilities, thereby ensuring continuity in clinical medication and reducing the risks associated with drug switching due to centralized procurement [1] - Although some selected products have lower prices compared to previous sales, the selection of 13 products positions the company to maintain its market share and enhance the accessibility of these drugs if contracts are signed and executed [1]